A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Metformin Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
534
compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + metformin vs placebo + metformin
change in FPG from basline to W24, proportion of subjects receiving therapeutic response at W24, percent change of fasting lipid levels from baseline to W11/12, change in hs-CRP from baseline to W24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Local Institution
Anniston, Alabama, United States
Local Institution
Birmingham, Alabama, United States
Local Institution
Haleyville, Alabama, United States
Local Institution
Mobile, Alabama, United States
Local Institution
Mesa, Arizona, United States
Local Institution
Phoenix, Arizona, United States
Local Institution
Tucson, Arizona, United States
Local Institution
Fayette, Arkansas, United States
Local Institution
Little Rock, Arkansas, United States
Local Institution
Concord, California, United States
...and 193 more locations